helped shrink tumors in some patients with bile duct cancers—specifically a subset of people whose tumors make a high amount of the HER2 protein, which can cause cells to multiply too quickly., was a global, multicenter effort to evaluate the effectiveness and safety of zanidatamab, an antibody that works against the HER2 protein, in patients with HER2-amplifed bile duct cancer that has not responded to other treatment.
The most common side effects of the treatment were diarrhea and infusion-related reactions, such as allergic reactions, pain at the injection site, nausea, or flu-like symptoms . A small number of people had a decrease in heart function. No severe side effects were reported.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: